A Single-Arm Open-Label Multicenter Phase IV Clinical Trial to Explore the Blood Pressure Lowering Effect of Exforge (Amlodipine/Valsartan: AMLO/VAL) in Hypertensive Patients
Phase of Trial: Phase IV
Latest Information Update: 03 Apr 2017
Price : $35 *
At a glance
- Drugs Amlodipine/valsartan (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 21 Jul 2016 Status changed from recruiting to completed.
- 04 Aug 2014 Planned End Date changed from 1 Oct 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.
- 04 Aug 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.